Screening of the general population for cancer is a matter of primary prevention reducing the burden of disease. Whilst this is successful for several cancers including breast, colon and prostate, the situation to screen and hence prevent pancreatic cancer is different. The organ is not as accessible to simple physical exam or biological samples (fecal or blood test). Neither exists a blood test such as PSA that is cost-effective. Reviewing the evidence from screening risk groups for pancreatic cancer, one must conclude that there is no rational at present to screen the general population, for a lack of appropriate tests.
| Journal | Familial Cancer |
|---|---|
| Publisher | Springer |
| Publication Date | 2024-08-01 |
| Publication Year | 2024 |
| Volume | 23 |
| Issue | 3 |
| Pages | 399-403 |
| Document Type | Journal Article |
| eISSN | 1573-7292 |
| DOI | 10.1007/s10689-024-00363-6 |
| NARA Access Coverage | 2001-01-01~Current |
|---|---|
| Journal Homepage | https://www.springer.com/journal/10689 |
| Publisher Page | Open Publisher Page |